SystImmune and Bristol Myers report izalontamab brengitecan cuts progression or death risk by 59% in HR+/HER2- metastatic breast cancer

SystImmune and Bristol Myers Squibb reported a Phase 3 PANKU-Breast01 interim analysis showing izalontamab brengitecan reduced the risk of progression or death by 59% versus chemotherapy in HR+/HER2- metastatic breast cancer, with median PFS of 8.2 months versus 4.0 and an objective response rate of 40.5% versus 20.2%. Results will be presented at ESMO 2026.

Detected & updated continuously · Source: Nebula